Table 4

Clinical outcome

LTA5p Value
NPR (n=342)HCPR (n=137)HAPR (n=194)DAPR (n=248)
Death, MI, ST, stroke14 (4.1%)15 (10.9%)*17 (8.8%)†28 (11.3%)‡0.006
Death2 (0.6%)2 (1.5%)4 (2.1%)7 (2.8%)§0.19
MI10 (2.9%)11 (8.0%)¶11 (5.7%)20 (8.1%)#0.03
ST1 (0.3%)2 (1.5%)4 (2.1%)2 (0.8%)0.22
Stroke3 (0.9%)3 (2.2%)2 (1.0%)2 (0.8%)0.60
LTA20p Value
NPR (n=360)HCPR (n=120)HAPR (n=228)DAPR (n=215)
Death, MI, ST, stroke15 (4.2%)14 (11.7%)**22 (9.6%)††23 (10.7%)‡‡0.006
Death3 (0.8%)1 (0.8%)7 (3.1%)4 (1.9%)0.18
MI10 (2.8%)11 (9.2%)§§12 (5.3%)19 (8.8%)¶¶0.006
ST1 (0.3%)2 (1.7%)3 (1.3%)3 (1.4%)0.38
Stroke3 (0.8%)3 (2.5%)##4 (1.8%)0 (0.0%)0.12
VerifyNowp Value
NPR (n=218)HCPR (n=106)HAPR (n=36)DAPR (n=62)
Death, MI, ST, stroke9 (4.1%)10 (9.4%)2 (5.6%)11 (17.7%)***0.004
Death3 (1.4%)2 (1.9%)0 (0.0%)4 (6.5%)†††0.07
MI5 (2.3%)8 (7.5%)‡‡‡2 (5.6%)4 (6.5%)0.15
ST0 (0.0%)1 (0.9%)1 (2.8%)1 (1.6%)0.21
Stroke2 (0.9%)0 (0.0%)0 (0.0%)3 (4.8%)§§§ ¶¶¶0.03
  • LTA5: *p=0.009, †p=0.033, ‡p=0.001, §p=0.040, ¶p=0.023, #p=0.007; all vs NPR.

  • LTA20: **p=0.006, ††p=0.009, ‡‡p=0.003, §§p=0.007, ¶¶p=0.002; all vs NPR and ##p=0.045 vs DAPR.

  • VerifyNow: ***p=0.001, †††p=0.045, ‡‡‡p=0.033, all vs NPR, §§§p=0.049 vs HCPR and ¶¶¶p=0.048 vs HAPR.

  • DAPR, high on-aspirin and high on-clopidogrel platelet reactivity; HCPR, high on-clopidogrel platelet reactivity; HAPR, high on-aspirin platelet reactivity; LTA, light transmittance aggregometry; MI, myocardial infarction; NPR, normal on-treatment platelet reactivity according to aspirin and clopidogrel test; ST, stent thrombosis.